Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

Madiha Iqbal, MBBS, Aarushi Sharma, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, Aneel Paulus, MD

Blood (2018) 132 (Supplement 1): 5558.

https://doi.org/10.1182/blood-2018-99-120188

Published: 2018

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

Alak Manna, PhD, Sharoon Akhtar, MPhil, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Victoria R. Alegria, Taimur Sher, MD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 1736.

https://doi.org/10.1182/blood.V130.Suppl_1.1736.1736

Published: 2017

Journal Articles

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Thomas Caulfield, Alak Manna, PhD, Vivek Roy, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 3836.

https://doi.org/10.1182/blood.V130.Suppl_1.3836.3836

Published: 2017

Journal Articles

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Alak Manna, PhD, Sharoon Akhtar, MPhil, Zahara Meghji, Kirtipal Bhatia, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Taimur Sher, MD, Fabio Malavasi, MD, Victoria R. Alegria, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 3019.

https://doi.org/10.1182/blood.V130.Suppl_1.3019.3019

Published: 2017

Journal Articles

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Vivek Roy, MD, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1529.

https://doi.org/10.1182/blood.V130.Suppl_1.1529.1529

Published: 2017

Journal Articles

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Yamima Bashir, MBBS, Shumail M. Paulus, MBBS, Hassan Yousaf, Vivek Roy, MD, Sikander Ailawadhi, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 3018.

https://doi.org/10.1182/blood.V128.22.3018.3018

Published: 2016

Journal Articles

Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Roman Hudec, Shumail M. Paulus, MBBS, Yamima Bashir, MBBS, Thomas E. Witzig, MD, Stephen Ansell, MD PhD, Stig Linder, PhD, Sikander Ailawadhi, MD, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 2761.

https://doi.org/10.1182/blood.V128.22.2761.2761

Published: 2016

Journal Articles

Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Yamima Bashir, MBBS, Shumail M. Paulus, MBBS, Richa Menghani, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 4480.

https://doi.org/10.1182/blood.V128.22.4480.4480

Published: 2016

Journal Articles

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1279.

https://doi.org/10.1182/blood.V126.23.1279.1279

Published: 2015

Journal Articles

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Pooja Advani, MBBS, Thomas E. Witzig, MD, George J Weiner, MD, Sikander Ailawadhi, MD, Joachim Gullbo, MD PhD, Stig Linder, PhD, Geraldo Otero-Colon, Kasyapa S. Chitta, PhD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1557.

https://doi.org/10.1182/blood.V126.23.1557.1557

Published: 2015

Journal Articles

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Aneel Paulus, MDMS, Pooja Advani, MBBS, Betsy R. Laplant, MS, Sharoon Akhtar, MPhil, Taimur Sher, MD, Candido E. Rivera, MD, James M. Foran, MD, Vivek Roy, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 5299.

https://doi.org/10.1182/blood.V126.23.5299.5299

Published: 2015

Journal Articles

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Sharoon Akhtar, MPhil, Aneel Paulus, MDMS, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Vivek Roy, MD, Taimur Sher, MD, James M. Foran, MD, Candido E. Rivera, MD, Gerardo Colon-Otero, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 4839.

https://doi.org/10.1182/blood.V126.23.4839.4839

Published: 2015

Journal Articles

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

Aneel Paulus, MDMS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, MPhil, Hassan Yousaf, Davitte Cogen, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, James M. Foran, MD, Candido E. Rivera, MD, Taimur Sher, MD, Vivek Roy, MD, Sikander Ailawadhi, MD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 2754.

https://doi.org/10.1182/blood.V126.23.2754.2754

Published: 2015

Journal Articles

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Blood (2015) 126 (23): 703.

https://doi.org/10.1182/blood.V126.23.703.703

Published: 2015

Journal Articles

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

Abdel Kareem Azab, BPharm, PhD, Aneel Paulus, MDMS, Feda Azab, B.Pharm, Sharoon Akhtar, MPhil, Shireen Vali, PhD, Ansu Kumar, Neeraj Kumar Singh, Shweta Kapoor, Taher Abbasi, MS, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3024.

https://doi.org/10.1182/blood.V124.21.3024.3024

Published: 2014

Journal Articles

Therapeutic Sensitivity of CD20- Waldenströms Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Hyejin Yoon, Xue Wang, PhD, Maja Blake-Kuranz, Paul K. Wallace, MS, PhD, Sikander Ailawadhi, MD, Stephen M. Ansell, MD PhD, Anne J. Novak, PhD, Morie A Gertz, MD, Robert A Kyle, MD, Peter Martin, MD, Morton Coleman, MD, Jungsu Kim, PhD, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3115.

https://doi.org/10.1182/blood.V124.21.3115.3115

Published: 2014

Journal Articles

Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Maja Kuranz-Blake, B.S., Anne J. Novak, PhD, Stephen Ansell, MD, Morie A Gertz, MD, Robert A Kyle, MD, Peter Martin, MD, Morton Coleman, MD, Sikander Ailawadhi, MD, Stig Linder, MD PhD, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3116.

https://doi.org/10.1182/blood.V124.21.3116.3116

Published: 2014

Journal Articles

The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenströms Macroglobulinemia

Kasyapa S. Chitta, PhD, Aneel Paulus, MDMS, Maja Blake-Kuranz, Sharoon Akhtar, MPhil, Anne J. Novak, PhD, Stephen M. Ansell, MD PhD, Robert Kyle, MD MACP, Morie A Gertz, MD, Peter Martin, MD, Morton Coleman, MD, Sikander Ailawadhi, MD, Asher Chanan-Khan, MD

Blood (2014) 124 (21): 1689.

https://doi.org/10.1182/blood.V124.21.1689.1689

Published: 2014

Journal Articles

Methylation Patterns in Waldenströms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors

Aneel Paulus, MDMS, Xue Wang, PhD, Sharoon Akhtar, MPhil, Maja Kuranz-Blake, B.S., Anne Novak, PhD, Stephen M Ansell, MD, PhD, Morie A Gertz, MD, Robert A Kyle, MD, Peter Martin, MD, Morton Coleman, MD, Sikander Ailawadhi, MD, Asher Chanan-Khan, MD, Kasyapa S. Chitta, PhD

Blood (2014) 124 (21): 3551.

https://doi.org/10.1182/blood.V124.21.3551.3551

Published: 2014

NARROW

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance

Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma

In Silico Modeling of Oncogenic Drivers in Waldenstrom Macroglobulinemia to Assess Additional Therapeutic Targets within the BCR Signaling Pathway Identifies MEK1/2 As a Target: Potential Therapeutic Role of Binimetinib

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199

Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

A Novel and Personalized Method Using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

Therapeutic Sensitivity of CD20- Waldenströms Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events

Targeted Disruption of USP14 and UCHL5 with the Novel Deubiquitinase Enzyme (DUB) Inhibitor, VLX1570, Induces Immense Proteotoxicity and Cell Death in Malignant Plasma Cells

The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenströms Macroglobulinemia

Methylation Patterns in Waldenströms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only